Objectif Psychotic symptoms (hallucinations and delusions) have been associated with a striatal hyperdopaminergic state.Less explored, but also implicated are functional abnormalities in cognitive control, particularly in the prefrontal cortex; and a functional and structural disconnectivity between this and other areas of the brain.Such a disconnectivity would explain the lack of coherent response to conventional treatment: antipsychotic drugs do not benefit between 20 and 45 per cent of people with schizophrenia.The aim of this project is twofold: firstly, to explore the neural mechanisms underling cognitive control and the level at which cognitive control dysfunction operates in treatment refractory psychosis.The second is to test the hypothesis that cognitive dysfunction in patients who have treatment-resistant psychosis is associated with a specific neural signature – and discover whether that neural signature can be used as a biomarker of treatment resistance. Such a biomarker would help personalise treatment decisions and make treatment regimes more effective. It would also aid the development of novel treatments (other complementary work is investigating medication that enhances frontal cortical function as well as non-invasive brain stimulation techniques such as transcranial direct cortical stimulation).The project involves two linked brain imaging studies.The first will establish the indicative biomarker using both structural and functional MRI scanning and tasks to assess cognitive control at different levels of complexity.The second study will establish the validity of the biomarker by following a cohort of first episode psychosis patients for two years to discover whether their actual outcome corresponds with the outcome predicted by the neural signature shown in MRI scans. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinepsychiatryschizophrenia Programme(s) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) ERC-SG-LS5 - ERC Starting Grant - Neurosciences and neural disorders Appel à propositions ERC-2012-StG_20111109 Voir d’autres projets de cet appel Régime de financement ERC-SG - ERC Starting Grant Institution d’accueil KING'S COLLEGE LONDON Contribution de l’UE € 1 498 902,00 Adresse STRAND WC2R 2LS London Royaume-Uni Voir sur la carte Région London Inner London — West Westminster Type d’activité Higher or Secondary Education Establishments Contact administratif Paul Labbett (Mr.) Chercheur principal Sukhwinder Singh Shergill (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire KING'S COLLEGE LONDON Royaume-Uni Contribution de l’UE € 1 498 902,00 Adresse STRAND WC2R 2LS London Voir sur la carte Région London Inner London — West Westminster Type d’activité Higher or Secondary Education Establishments Contact administratif Paul Labbett (Mr.) Chercheur principal Sukhwinder Singh Shergill (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée